Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Anna Kotzeva, Deepali Mittal, Supriya Desai, Davneet Judge & Kunal Samanta. (2023) Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics 26:1, pages 70-83.
Read now
Read now
Benjamin Kearns, Katy Cooper, Anna Cantrell & Chloe Thomas. (2021) Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment 17, pages 125-137.
Read now
Read now
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Bertalan Németh, Ahmad Fasseeh, Anett Molnár, István Bitter, Margit Horváth, Kristóf Kóczián, Árpád Götze & Balázs Nagy. (2018) A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 267-275.
Read now
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Articles from other publishers (17)
Luying Wang, Fenghao Shi, Xin Guan, He Xu, Jing Liu & Hongchao Li. (2021) A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. Frontiers in Public Health 9.
Crossref
Crossref
Ruth A. Lewis, Dyfrig Hughes, Alex J. Sutton & Clare Wilkinson. (2020) Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. PharmacoEconomics 39:1, pages 25-61.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, David Aceituno & Sarah Byford. (2020) Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. PLOS ONE 15:7, pages e0234996.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
Reinhold Kilian, Karel Frasch, Tilman Steinert, Wiltrud Schepp, Prisca Weiser, Susanne Jaeger, Carmen Pfiffner, Gerhard W. Eschweiler, Thomas Messer, Daniela Croissant, Gerhard Längle & Thomas Becker. (2018) Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial. Neurology, Psychiatry and Brain Research 30, pages 47-55.
Crossref
Crossref
Charles Nguyen, Andrei Novac, Jessica Hazen, Pamela Howard, Ryan Tieu & Robert G Bota. (2017) Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole–antidepressant polypharmacy in an outpatient sample. Journal of Psychopharmacology 32:4, pages 423-429.
Crossref
Crossref
Elsa Rodríguez Angulo, Guadalupe Andueza Pech & Rita Zapata Vázquez. (2018) Global risk of death due to delays in the care of pregnant women with obstetric complication in yucatan, Mexico. Obstetrics & Gynecology International Journal 9:2.
Crossref
Crossref
Mark Pennington & Paul McCrone. (2017) The Cost of Relapse in Schizophrenia. PharmacoEconomics 35:9, pages 921-936.
Crossref
Crossref
Krithika Rajagopalan, David Trueman, Lydia Crowe, Daniel Squirrell & Antony Loebel. (2016) Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics 34:7, pages 709-721.
Crossref
Crossref
Hoover Quitian Reyes, Jair Alberto Arciniegas Barrera, Adriana Bohórquez Peñaranda & Carlos Gómez Restrepo. (2016) Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia. Revista Colombiana de Psiquiatría 45:2, pages 67-74.
Crossref
Crossref
Juan Carlos Rejon-Parrilla, Mark Nuijten, William K. Redekop & Jennifer G. Gaultney. (2014) Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. Health Policy and Technology 3:4, pages 314-324.
Crossref
Crossref
Taehwan Park & Karen M. Kuntz. (2014) Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. Value in Health 17:4, pages 310-319.
Crossref
Crossref
Michael Sonntag, Hans-Helmut König & Alexander Konnopka. (2013) The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review. PharmacoEconomics 31:12, pages 1131-1154.
Crossref
Crossref
F. Kasteng, J. Eriksson, K. Sennfält & P. Lindgren. (2011) Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica 124:3, pages 214-225.
Crossref
Crossref
Sebastian Braun, Jan Zeidler, Thomas Mittendorf & J. -Matthias Graf von der Schulenburg. (2013) Kosteneffektivität von Quetiapin und Haloperidol bei Patienten mit partiell therapieresistenter SchizophrenieCost-effectiveness analysis of quetiapine and haloperidol for partial responders in schizophrenia. PharmacoEconomics German Research Articles 8:1, pages 21-29.
Crossref
Crossref
Christina M. van der Feltz-Cornelis. 2010. Ethics in Psychiatry. Ethics in Psychiatry
33
54
.
Hans Joachim Salize, Rosemarie McCabe, Jens Bullenkamp, Lars Hansson, Christoph Lauber, Rafael Martinez-Leal, Iris Reinhard, Wulf Rössler, Bengt Svensson, Francisco Torres-Gonzalez, Rob van den Brink, Durk Wiersma & Stefan Priebe. (2009) Cost of treatment of schizophrenia in six European countries. Schizophrenia Research 111:1-3, pages 70-77.
Crossref
Crossref